Defect-Rich Platinum-Zinc Oxide Heterojunction as a Potent ROS Amplifier for Synergistic Sono-Catalytic Therapy.
Defect-Rich Platinum-Zinc Oxide Heterojunction as a Potent ROS Amplifier for Synergistic Sono-Catalytic Therapy.
复制标题
DOI：
10.1016/j.actbio.2023.09.032
复制
发表时间：
2023-09
影响因子：
9.7
通讯作者：
Yuxuan Li;Wenxin Li;Yianghao Liu;Jiahui Liu;Xinru Yuan;Jiarui Zhang;Heyun Shen
中科院分区：
文献类型：
--
作者：
Yuxuan Li;Wenxin Li;Yianghao Liu;Jiahui Liu;Xinru Yuan;Jiarui Zhang;Heyun Shen
声动力疗法（SDT）是一种物理疗法，利用超声触发的关键声敏剂来实现有效的非侵入性肿瘤治疗。然而，传统无机声敏剂的声动力学效应不足和响应活性低，阻碍了其实际应用。在这里，我们合理地设计了一种铂-锌氧化物（Pt单键ZnO）声敏剂，通过其固有的带隙结构和双纳米酶活性显着提高SDT的功效。Pt单键ZnO具有较窄的禁带宽度（2.89 eV）和适量的氧缺陷，在超声辐照下，这些缺陷促进了电子和空穴的分离效率和活性氧（ROS）的产生。同时，Pt单键ZnO同时具有过氧化氢酶和过氧化物酶活性，能有效催化内源性H2 O2生成大量O2和毒性羟基自由基（·OH），从而实现SDT的高效增强和催化治疗。此外，Pt单键ZnO具有显著的谷胱甘肽消耗性能，进一步放大了氧化应激。最终，Pt单键ZnO实现了三重ROS放大效应，单线态氧（1 O2）和·OH的产率分别达到859.1%和614.4%，诱导了高效的声催化治疗，肿瘤抑制率达到98.1%。本研究拓展了ZnO半导体异质结在纳米医学领域的应用，而Pt单键ZnO的简单而有效的设计为声敏剂的开发提供了一种策略。重要性声明构建了一种具有双纳米酶活性的铂-氧化锌（Pt单键ZnO）异质结声敏剂，实现了三重ROS放大效应，从而实现了高效的协同声催化治疗。Pt单键ZnO具有固有的窄带隙和丰富的氧缺陷，因此表现出有效的声敏性能。同时具有过氧化氢酶和过氧化物酶活性，能有效地催化内源性H2 O2转化为大量的O2和有毒的羟基自由基，从而增强SDT和催化治疗作用。此外，其突出的谷胱甘肽消耗性能进一步放大氧化应激。单线态氧和羟基自由基的产率分别高达859.1%和614.4%，诱导了高效的声催化治疗，肿瘤抑制率高达98.1%。
Sonodynamic therapy (SDT) is a physical therapy that utilizes critical sonosensitizers triggered by ultrasound to achieve an effective non-invasive tumor treatment. However, the inadequate sonodynamic efficacy and low responsive activities of traditional inorganic sonosensitizers have hindered its practical application. Here, we rationally design a platinum–zinc oxide (Ptsingle bondZnO) sonosensitizer to significantly enhance the efficacy of SDT through its inherent bandgap structure and dual-nanozyme activities. The Ptsingle bondZnO possesses a narrow bandgap (2.89 eV) and an appropriate amount of oxygen defects, which promote the efficiency of electrons and holes separation and the generation of reactive oxygen species (ROS) under US irradiation. Simultaneously, the Ptsingle bondZnO exhibits both catalase-like and peroxidase-like activities, which effectively catalyze endogenous H2O2into a large number of O2and toxic hydroxyl radicals (•OH), thus achieving an efficient enhancement of SDT and catalytic therapy. Moreover, the Ptsingle bondZnO has significant glutathione consumption performance, further amplifying the oxidative stress. Ultimately, the Ptsingle bondZnO achieves a triple ROS amplification effect, with the yields of singlet oxygen (1O2) and •OH reaching 859.1 % and 614.4 %, respectively, inducing a highly effective sono-catalytic therapy with a remarkable tumor inhibition rate of 98.1 %. This study expands the application of ZnO semiconductor heterojunctions in the nanomedicine area, and the simple yet efficient design of the Ptsingle bondZnO provides a strategy for the development of sonosensitizers.Statement of significanceA platinum-zinc oxide (Ptsingle bondZnO) heterojunction sonosensitizer is constructed with dual-nanozyme activities and achieves a triple ROS amplification effect, leading to an efficient synergistic sono-catalytic therapy. The Ptsingle bondZnO owns an inherent narrow bandgap and abundant oxygen defects, thus exhibiting an efficient sonosensitizer performance. It also possesses both catalase-like and peroxidase-like activities, which effectively catalyze the endogenous H2O2into a large quantity of O2and toxic hydroxyl radicals, thereby enhancing the SDT and catalytic therapy. Furthermore, its prominent glutathione consumption performance further amplifies oxidative stress. The yields of singlet oxygen and hydroxyl radicals reach up to 859.1 % and 614.4 %, respectively, inducing a highly effective sono-catalytic therapy with an impressive tumor inhibition rate of 98.1 %.